[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"preeclampsia-postpartum\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:preeclampsia-postpartum":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,77,100,127,148,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100629698","phase-4-biomarkers-in-management-of-post-partum-preeclampsia-100629698",false,"NCT07478055","Biomarkers in Management of Post Partum Preeclampsia","Biomarkers in Management of PP Preeclampsia","Inclusion Criteria:\n\n* The study population will consist of pregnant people ages 18 to 45 years old undergoing delivery in setting of preeclampsia with severe features as the experimental group and control (standard of care) groups\n* Diagnosis of PreEclampsia with severe featues must be made by standard clinical guidelines based on symptoms (persistent headache not responsive to medications, persistent right upper quadrant pain not responsive to medications), laboratory values (creatinine \\>1.1mg\u002FdL or twice the participants' baseline, AST or ALT \\> twice the upper limit of normal or twice patient's blood line, platelets \\\u003C100,000), or blood pressure criteria (Systolic \\>160 mmHg or Diastolic \\>110mmHg persistent over 15 minutes such that short acting antihypertensives are required, or Systolic \\>160mmHg or Diastolic\\>110mmHg present 4 hours or more apart)\n\nExclusion Criteria:\n\n* Exclusion criteria included Hemolysis Elevated Liver enzymes Low Platelets (HELLP) Syndrome, pulmonary edema, chronic or acute kidney injury, eclampsia, worsening neurologic symptoms, medical contraindication to magnesium (ex. Myasthenia Gravis)\n* Multiple gestations (twins, triplets, etc)\n* Inability to consent in English","FEMALE","18 Years","45 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Participants are recruited for a research study about how lab values change following delivery in people with Preeclampsia with Severe Features. Preeclampsia with Severe Features means that the disease has impacted organs, causing high blood pressures, symptoms, or changes in lab values. Those with Preeclampsia with Severe Features receive magnesium sulfate after delivery.\n\nThe study is intended to learn how lab values change following delivery and to investigate how quickly participants get better from preeclampsia. Participation in this research will last while admitted to the hospital. Information will be collected from the post partum visit, but there is no need for blood draw at that time. The purpose of this research is to gather information on the safety and effectiveness of a shorter administration of magnesium which is approved by the Food and Drug Administration (FDA).\n\nParticipants will be randomized into two groups, which means that it will be decided by chance if 12 hours or 24 hours of magnesium will be given after the delivery of the baby.\n\nBlood samples will be collected at time of delivery, 12 hours after delivery, 18 hours after delivery, 24 hours after delivery, and then daily. This is very similar to the number of labs to be collected even if participants decide not to participate in this study. This would likely add 2 or 3 blood draws. Both groups will have the same number of blood draws collected.\n\nOther than possibly having 12 hours of magnesium, and a few more blood draws, the rest of the care received will not change. Each blood draw will consist of \\~10mL, meaning a total of about 40mL of blood would be drawn for the purpose of this study.\n\nData would be collected, and deidentified. Information collected would include age, other medical conditions (like diabetes or high blood pressure out side of pregnancy), blood pressure, and symptoms during hospital stay and at the post partum visit.",[27,28],"Preeclampsia Severe","Preeclampsia Postpartum",[30,31,32,33],"PreEclampsia","Magnesium Sulfate","Post Partum","PreEclampsia with Severe Features","NOT_YET_RECRUITING","2026-05-27",{"date":37,"type":38},"2026-06-01","ACTUAL",{"date":40,"type":21},"2026-06",{"date":42,"type":21},"2027-08-31",{"name":44,"class":45},"Alexander Harrison","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":46},"100399275","phase-4-aspirin-and-preeclampsia-100399275","NCT04479072","Aspirin and Preeclampsia","Aspirin to Prevent Cardiac Dysfunction in Preeclampsia","Inclusion Criteria:\n\n1. Pregnant Adults between 18 and 45 years of age\n2. Diagnosed with preeclampsia\n3. Presenting for delivery with a singleton gestation.\n\nExclusion Criteria:\n\n1. We will exclude patients in labor\n2. Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation\n3. Plan to deliver outside of the participating site\n4. Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI.\n5. Aspirin allergy\n6. Clear indication for aspirin therapy or contraindication to aspirin therapy\n7. Clinically significant conditions that might limit adherence to trial regimen (e.g., peptic ulcer disease, history of gastrointestinal bleeds, bleeding disorders)\n8. Currently or planning on taking any nonsteroidal anti-inflammatory drugs while they are participating in this study.\n9. Those who cannot provide consent",{"count":55,"type":21},180,[24],"This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve (GLS) in preeclamptic patients.",[28],[60,61,62,63,64,65,66],"Preeclampsia","Postpartum GLS Levels","Postpartum Activin A Levels","Aspirin","Cardiac Postpartum Therapy","Hypertension","Cardiovascular disease","RECRUITING","2026-04-28",{"date":70,"type":38},"2026-05-04",{"date":72,"type":38},"2021-02-15",{"date":74,"type":21},"2026-12-31",{"name":76,"class":45},"University of Chicago",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":46},"100573679","early-phase-1-vascular-effects-of-high-salt-after-preeclampsia-100573679","NCT06749418","Vascular Effects of High-Salt After Preeclampsia","Role of the Mineralocorticoid Receptor in Microvascular Endothelial Dysfunction After Preeclampsia","Inclusion Criteria:\n\n* women who had preeclampsia and women who did not have preeclampsia\n* 12 weeks to 5 years postpartum\n* 18-45 years old\n\nExclusion Criteria:\n\n* history of hypertension or metabolic disease before pregnancy\n* history of gestational diabetes\n* history of gestational hypertension without preeclampsia\n* skin diseases\n* current tobacco use\n* current antihypertensive medication\n* statin or other cholesterol-lowering medication\n* currently pregnant\n* body mass index less than 18.5 kg\u002Fm2\n* allergy to materials used during the experiment.(e.g. latex),\n* known allergy to study drugs or salt-supplement",true,{"count":86,"type":21},40,[88],"EARLY_PHASE1","Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. Importantly, women who had preeclampsia have an exaggerated vascular responsiveness to hypertensive stimuli, such as high-salt intake, compared to women who had a healthy pregnancy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. While the association between a history of preeclampsia and vascular dysfunction leading to elevated CVD risk is well known, the mechanisms underlying this dysfunction remains unclear.\n\nThe purpose of this study is to examine the role of vascular mineralocorticoid receptor, the terminal receptor in the angiotensin system that contributes to blood pressure regulation, in mediating exaggerated microvascular endothelial dysfunction before and after a high-salt stimulus. This will help us better understand the mechanisms of microvascular dysfunction these women, and how inhibition of these receptors may improve microvascular function.\n\nIn this study, we use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) we examine the blood vessels in a nickel-sized area of the skin.",[60,28],"2026-02-10",{"date":93,"type":38},"2026-02-13",{"date":95,"type":38},"2025-01-02",{"date":97,"type":21},"2027-11-15",{"name":99,"class":45},"Anna Stanhewicz, PhD",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":46},"100605848","phase-4-optimizing-preeclampsia-postpartum-with-point-of-care-ultrasound-100605848","NCT07167862","Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound","Optimizing Preeclampsia Postpartum With Point-of-Care Ultrasound: A Pilot Prospective Cohort Study","PPPOCUS","Inclusion Criteria:\n\nHistorical cohort (group 1):\n\n* Age greater than or equal to 18 years at the time of delivery\n* Diagnosis of preeclampsia (without severe features, with severe features, HELLP syndrome, eclampsia) during pregnancy\n* Gestational age greater than or equal to 20 weeks' gestation at delivery\n* Delivery at the study institution within the 18-month period prior to implementation of the study's POCUS intervention\n* Available and complete postpartum clinical data on: Daily blood pressure, diuretic or antihypertensive use, length of postpartum hospital stay, readmission within 30 days of primary hospitalization\n\nProspective cohorts (groups 2 and 3):\n\n* Age greater than or equal to 18 years at the time of enrollment\n* Diagnosis of preeclampsia (without severe features, with severe features, HELLP syndrome, eclampsia) made up until 24 hours postpartum Postpartum and within 24 hours of delivery\n\nExclusion Criteria:\n\nHistorical cohort (group 1):\n\n* Delivery at an outside facility or incomplete postpartum records available for analysis\n* Pre-existing diagnosis of chronic hypertension; selected to mirror prospective cohort exclusion criteria (see below).\n* Documentation of chronic kidney disease (CKD stage 3 or higher); selected because diuresis is more likely to be avoided in this patient population even in the presence of physical exam findings suggesting volume overload.\n* Documentation of postpartum complications unrelated to preeclampsia that may significantly alter hemodynamics (e.g., sepsis, postpartum hemorrhage); selected because diuresis is more likely to be avoided in this patient population even in the presence of physical exam findings suggesting volume overload.\n\nProspective cohorts (groups 2 and 3):\n\n* Pre-existing diagnosis of chronic hypertension; selected because previous studies on furosemide use in patients with postpartum preeclampsia have found a significant reduction in hypertension among patients with newly diagnosed hypertensive disorders of pregnancy, but not among those with pre-gestational hypertension, meaning that inclusion of this population might reduce the magnitude of study effects.\n* Baseline renal dysfunction with serum creatinine \\> 1.1 mg\u002FdL; selected as this laboratory finding has been pre-selected as a safety outcome.\n* Baseline hypokalemia with serum potassium \\\u003C 3.5 mEq\u002FL despite previous repletion with intravenous or oral potassium chloride; selected as this laboratory finding has been pre-selected as a safety outcome.\n* Known hypersensitivity to furosemide or sulfa drugs; selected because this would preclude exposure to the study medication of interest.\n* Current use of diuretics for other indications (e.g. heart failure); selected because this may require a furosemide or other diuretic regimen different from that planned for the study intervention.",{"count":109,"type":21},96,[24],"This study explores a novel approach to improving care for postpartum patients with preeclampsia, a pregnancy-related condition characterized by high blood pressure, protein in the urine, and organ dysfunction. Preeclampsia affects up to 9% of pregnancies and can progress to include complications of seizures, stroke, and even death. Over 60% of patients with preeclampsia continue to experience high blood pressure at the time of discharge from their delivery hospitalization, and many of these patients require blood pressure medications for up to 6 months postpartum. Even with blood pressure medications, many of these patients are readmitted to the hospital within six weeks of delivery.\n\nIn this study, the investigators will utilize point-of-care ultrasound (POCUS), a quick and non-invasive, bedside imaging strategy, to look for signs of excess fluid accumulating in the lungs and venous system of postpartum patients with preeclampsia. Because excess fluid has the potential to worsen blood pressure, subjects with evidence of this on POCUS would be treated with a diuretic medication called furosemide (either orally or intravenously) within 24 hours of delivery.\n\nThe investigators' main goal is to determine whether using POCUS can help physicians make better treatment decisions and improve short-term outcomes for postpartum patients with preeclampsia. The investigators' aim to achieve faster recovery of blood pressure, reduce the need for blood pressure medication at hospital discharge, and lower the rates of hospital readmission for those with preeclampsia. This study could significantly enhance the overall care and health of postpartum patients.",[60,28,113],"Preeclampsia Severe or Mild",[60,115,116,117],"Postpartum","Point of care ultrasound","Diuretics","2026-01-22",{"date":120,"type":38},"2026-01-23",{"date":122,"type":21},"2026-06-15",{"date":124,"type":21},"2028-06-15",{"name":126,"class":45},"University of California, Irvine",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":84,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":46},"100336968","phase-2-postpartum-low-dose-aspirin-and-preeclampsia-100336968","NCT03667326","Postpartum Low-Dose Aspirin and Preeclampsia","Low-Dose Aspirin in the Postpartum Period and Endothelial Function in Patients With Preeclampsia","Inclusion Criteria:\n\n* Singleton or Multiple gestation\n* Maternal age \\>= 18 years\n* 20 0\u002F7 weeks gestation or greater\n* Severe Preeclampsia diagnosed prior to delivery\n\nExclusion Criteria:\n\n* Aspirin use postpartum for other medical indication\n* Lovenox, unfractionated heparin, or other anticoagulant use postpartum for an indication other than postoperative (in-house)\n* Aspirin use within 7 days of planned initial FMD testing postpartum\n* Hypersensitivity or allergy to Aspirin or other salicylates\n* Hypersensitivity or allergy to nonsteroidal anti-inflammatory drugs (NSAIDs) - exception if taking LDA in pregnancy\n* Nasal polyps\n* Gastric or Duodenal ulcers, history of GI bleeding\n* Severe hepatic dysfunction\n* Bleeding disorders and diathesis\n* Breastfeeding a newborn with low platelets (NAIT)\n\nFor sub-study patients, inclusion and exclusion criteria will be the same, with the exception of diagnosis of severe preeclampsia prior to delivery (exclusion criterion for healthy controls group).",{"count":20,"type":21},[136],"PHASE2","The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg) or placebo to take daily for up to 3 weeks post-delivery. Exploratory objective includes healthy control postpartum patients without preeclampsia and not on LDA during pregnancy or postpartum in comparison with the primary study population affected by preeclampsia with severe features.",[28],[63],"2026-01-21",{"date":118,"type":38},{"date":143,"type":38},"2019-07-22",{"date":145,"type":21},"2026-12",{"name":147,"class":45},"Columbia University",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":84,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":165,"locationsCount":46},"100511315","early-phase-1-sensitivity-of-angiotensin-ii-type-ii-receptors-in-women-following-preeclampsia-100511315","NCT05937841","Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia","Inclusion Criteria:\n\n* women who had preeclampsia and women who did not have preeclampsia\n* 12 weeks to 5 years postpartum\n* 18-45 years old\n\nExclusion Criteria:\n\n* history of hypertension or metabolic disease before pregnancy\n* history of gestational diabetes\n* skin diseases\n* current tobacco use\n* current antihypertensive medication\n* statin or other cholesterol-lowering medication\n* currently pregnant or planning to become pregnant\n* body mass index less than 18.5 kg\u002Fm2\n* allergy to materials used during the experiment.(e.g. latex),\n* known allergy to study drugs",{"count":155,"type":21},30,[88],"Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. Identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women.\n\nThe purpose of this study is to examine the microvascular differences in women who have had preeclampsia following activation of protective angiotensin receptors in the skin. This will help increase understanding of the mechanisms of angiotensin II receptors in these women, and how activation of these receptors may restore microvascular function.\n\nIn this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.",[28],"2025-08-19",{"date":161,"type":38},"2025-08-24",{"date":163,"type":38},"2023-06-28",{"date":37,"type":21},{"name":99,"class":45},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":187,"locationsCount":46},"100510325","phase-2-aspirin-for-postpartum-patients-with-preeclampsia-100510325","NCT05924971","Aspirin for Postpartum Patients With Preeclampsia","Acetylsalicylic Acid for Postpartum Preeclampsia: A Pilot Randomized Trial","ASAPP","Inclusion Criteria:\n\n* Preeclampsia with severe features diagnosed during delivery admission, as defined by ACOG criteria.\n* Pre- and postnatal care provided by the Long Beach Memorial Ob\u002FGyn resident or Maternal-Fetal Medicine clinic.\n\nExclusion Criteria:\n\n* Patient age \\\u003C18 years old\n* Non-English or Non-Spanish speaking\n* Chronic hypertension diagnosed before 20 weeks' gestation\n* Known allergy, prior adverse reaction, or any medical condition in which aspirin is contraindicated (nasal polyps, gastric or duodenal ulcers, history of gastrointestinal bleeding, severe hepatic dysfunction)\n* Aspirin prescribed postpartum for any other medical condition\n* Bleeding disorder\n* Breastfeeding an infant with thrombocytopenia",{"count":175,"type":21},86,[136],"The purpose of this research study is to evaluate the effect of low-dose aspirin on recovery from severe preeclampsia (a high blood pressure disorder of pregnancy) among women who have given birth. We hypothesize that taking aspirin for the first week after giving birth will enhance recovery from preeclampsia by decreasing the levels of a protein called soluble fms-like tyrosine kinase (sFlt-1), which is thought to be a main contributor to the development of preeclampsia, and speeding up return to a normal blood pressure.",[28],[60,115,63,180],"sFlt-1","2025-06-03",{"date":183,"type":38},"2025-06-06",{"date":185,"type":38},"2023-07-26",{"date":145,"type":21},{"name":188,"class":45},"MemorialCare Health System"]